Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.Salah-Eddin Al-Batran, Timo Gaiser, Peter Thuss‐Patience et al.|Journal of Clinical Oncology|2022Cited by 96